H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1

Core Insights - Structure Therapeutics Inc. (NASDAQ:GPCR) is gaining attention as a promising investment opportunity, with multiple analysts raising their price targets significantly due to strong growth potential and favorable market conditions [1][2][3] Analyst Ratings and Price Targets - H.C. Wainwright raised its price target on Structure Therapeutics to $90 from $60, citing a validated titration strategy and significant arbitrage opportunity compared to industry metrics [1] - Morgan Stanley increased its price target to $125 from $120, maintaining an Overweight rating, and noted that regulatory uncertainties affecting the biopharma sector are expected to diminish in 2026 [2] - Jefferies also raised its price target to $125 from $79, highlighting the positive Phase 2b data for aleniglipron and positioning Structure Therapeutics as a leader in the oral GLP-1 space [3] Company Overview - Structure Therapeutics is a clinical-stage global biopharmaceutical company focused on developing novel oral small-molecule therapeutics for chronic diseases with unmet medical needs in the US [4] Market Position and Growth Potential - The company is seen as having strong M&A potential and encouraging Phase 2 data, positioning it well for future growth or acquisition opportunities [1]